Logo Bioteck Academy

Dentistry and Maxillofacial


Subscribe to
our Newsletter
Author : Vražić D.

The use of Equine enzymatically deantigenated bone substitutes in the treatment of intrabony defects

The aim of this study was to evaluate the use of collagen type I in hydrogel that contains vascular endothelial growth factor (VEGF) combined with an equine bone substitute (Osteoplant Angiostad) in the treatment of intrabony defects in periodontitis patients.  24 patients with intrabony periodontal defects of ≥4 mm participated in this study. Patients were randomly selected to two groups. In conjunction with papilla preservation flaps one group (14 patients) received Osteoplant Angiostad and equine demineralized bone mineral with a membrane while the other group (10 patients) did not receive a membrane. Baseline probing pocket depths (PPD), recessions (REC) and clinical attachment levels (CAL) were recorded. Plaque and bleeding scores were below 25%.The paired t test was utilized to evaluate differences between the treatment groups and baseline. The level of significance was set at p<0.05. 1-year after treatment patients in the membrane group showed a reduction in mean PPD from 9.2±2.7 to 3.9±1.4 mm, increase in REC from 1.1±1.3 to 1.6±1.6 mm and CAL from 10.3±2.4 to 5.3±1.4 mm, with a CAL gain of 4.85±2.2 mm. In the non-membrane group the mean PPD changed from 7.8±0.9 mm to 3.8±1.3 mm, REC from 0.14±0.4 to 0.6±0.9 mm and CAL from 7.9±1.0 to 4.4±1.4 mm, with a CAL gain of 3.5±1.0 mm. Results demonstrated statistically greater PPD reduction and CAL gain (p<0.05) in both groups as compared to baseline. Results after 1-year demonstrated statistically greater PPD reduction and CAL gain (p<0.05) in the both groups following treatment. The addition of a resorbable membrane further enhanced CAL gain, although patients in this group had initially deeper PPD which could account for the difference in CAL gains between the groups. This treatment modality leads to significantly improved clinical outcomes in treating intrabony defects.

PRODUCTS USED: Osteoplant Angiostad OGS-GEL1, OGS-GEL2

Journal of Dental Research, 90 (Spec Iss A) -Proceedings of General Session & Exhibition of the International Association for Dental Research - San Diego, SAD, 16-19.03.2011

Subscribe to our Newsletter

  • Hidden
Logo Bioteck Academy

via E. Fermi, 49
36057 Arcugnano, Vicenza (VI) - Italy
Tel. +39 0444 289366
Fax: +39 0444 285272

Contact us

Multi-function production center
Via G. Agnelli, 3
10020 Riva presso Chieri, Torino (TO) - Italy

Copyright © 2024 Bioteck S.p.A. - Privacy Policy - Cookie Policy